Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced its operating results for the second quarter and six months ended June 30, 2013. Revenue and other income for the second quarter of 2013 was approximately $338,000, including $116,000 in sales of...
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), developer of a rapid and painless testing platform that uses biophotonics for the early detection of disease, today announced that it is scheduled to report financial results for its second quarter ended June 30,...
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today commented on the status of its Pre-market Approval (PMA) application for the LuViva® Advanced Cervical Scan. While the Company requested a phone meeting with the U.S. Food and Drug Administration (FDA) after...
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) and its Turkish distributor, I.T.E.M. Medical Technologies Group, today announced a major program for early detection and prevention of cervical cancer involving Guided Therapeutics’ LuViva® Advanced Cervical Scan....
Up to 40 percent of women currently undergoing unnecessary procedures for cervical disease diagnosis could avoid the psychological and financial burdens and the potential for medical complications from treatment if given a non-invasive test with the LuViva® Advanced...
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that it has entered into definitive agreements with certain accredited investors for the private placement of its convertible preferred stock and warrants to purchase shares of its common stock....
